Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Providing Genomic Testing for Pharmatech's Cancer Registry

NEW YORK (GenomeWeb) – Paradigm today announced it has initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

Non-profit diagnostics shop Paradigm offers a next-generation sequencing-based cancer test called PCDx that sequences both DNA and RNA. It will provide the test for patients that are enrolled in Pharmatech's AccessPPM, a cancer registry that collects electronic medical record data and genomic information to match cancer patients with targeted clinical trials.

"We believe AccessPPM will change the way today's oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research," Pharmatech CEO Rob Bohacs said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.